$CRVS
Corvus Pharmaceuticals Inc
PRICE
$1.085 β²0.935%
Last Close
VOLUME
268,392
DAY RANGE
1.06 - 1.1
52 WEEK
0.7501 - 9.54
Join Discuss about CRVS with like-minded investors
@Matthias_Knopf #T|T|T
Ok ich lass es. keine Trades mehr. Intraday komm ich einfach auf keine CRVs die man da benΓΆtigen wΓΌrde :)
46 Replies 14 π 7 π₯
@Baljit123 #StockTraders.NET
MIC CHRIS LEE WATCHLIST. Not many I really like its been slow and no follow through on the runners 1. CRVS multi day runner had a nice FGD we will see if we can get some continuation 2. IRNT they seem to be trying to push this up PR;s keep coming out with PT raises 3. OPAD still hovering the 10 line just watching 4. ATER still holding the multiday uptrend and reclaimed the 10 day and above the 20 day on the daily might make another bun at 20 line and the daily range is getting tighter 5. DNA is SPAC merger it has been on a multiday uptrend if it gets over the 14.25 ATH could see a nice move but this is not really the market for strong continuation so we will have to watch and see
47 Replies 8 π 9 π₯
@TraderXx #StockTraders.NET
$CRVS might have a trick up it sleeve towards EOD, expecting some kinda blast and a sit back
53 Replies 6 π 9 π₯
@TraderXx #StockTraders.NET
I see $CRVS being forgotten kinda, need to keep an eye on this one
135 Replies 15 π 7 π₯
@maletone #StockTraders.NET
sold most my $CRVS but wished i went short after I sold lol
131 Replies 11 π 11 π₯
Key Metrics
Market Cap
50.28 M
Beta
0
Avg. Volume
311.74 K
Shares Outstanding
46.55 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.
CEO: Richard Miller
Website: www.corvuspharma.com
HQ: 863 Mitten Rd Ste 102 Burlingame, 94010-1311 California
Related News